2025-02-04
PSMA, a revolution against prostate cancer
Oncology
#ProstateCancer #Cancer #Prostate #Therapy #Innovation #PSMATargetedTherapy #Immunotherapy
Prostate cancer is one of the most common cancers in men and remains a leading cause of cancer-related mortality worldwide. With increasing life expectancy and improved screening techniques, its incidence continues to rise. While conventional treatments—hormone therapy, chemotherapy, and radiotherapy—can control the disease in its early stages, their effectiveness significantly declines as the cancer progresses into more aggressive forms.
Metastatic castration-resistant prostate cancer (mCRPC) exemplifies this challenge. This advanced stage of the disease is characterized by loss of sensitivity to hormonal treatments, leading to uncontrolled tumor progression, often accompanied by bone and visceral metastases. This resistance is driven by complex mechanisms, such as alterations in androgen signaling pathways or tumor mutations that promote therapeutic escape. The available treatments for mCRPC patients are therefore limited and show reduced long-term efficacy. It is crucial to develop innovative and targeted approaches to improve patient management.
In this context, prostate-specific membrane antigen (PSMA) has emerged as a key target in the fight against prostate cancer. Highly overexpressed in tumor cells, PSMA has transformed diagnostic and therapeutic approaches, enabling precise detection and effective targeting of cancer cells. Among the major advancements, radioligand therapy (RLT) using lutetium-177 ([177Lu]Lu-PSMA-617) has demonstrated promising results, particularly in the treatment of mCRPC.
The safety and efficacy of treatments were also assessed, with particular attention to side effects (renal and hematological toxicities). The trials included mCRPC patients, meeting strict criteria (ECOG score ≤ 2 and confirmed PSMA overexpression by molecular imaging). The results were compared to conventional treatments to evaluate the specific benefits of PSMA-targeting approaches.
The study results demonstrate that PSMA-targeted therapies have led to a significant improvement in overall survival (OS) and radiographic progression-free survival (rPFS) in mCRPC patients. The VISION trial reported an increase in rPFS by 5.3 months and OS by 4 months compared to standard treatments. However, approximately 17% to 30% of patients exhibit primary resistance to this therapy, primarily due to tumor heterogeneity and immune escape mechanisms.
The results show that this revolutionary therapy enhances survival prospects for patients with advanced cancers, but remains limited by significant challenges. Common toxicities, high costs, and the complex production of radiopharmaceuticals hinder its widespread adoption.
Despite these limitations, promising research is focusing on optimizing PSMA-targeted therapy. The combination with immune checkpoint inhibitors (PD-1/PD-L1) or DNA repair agents could enhance its efficacy and overcome resistance. Furthermore, the exploration of alternative isotopes opens new perspectives for increased efficacy and reduced side effects. With ongoing clinical trials and continuous advancements, PSMA-targeted therapy is well-positioned to transform the management of advanced or resistant prostate cancers.
Prostate cancer is one of the most common cancers in men and remains a leading cause of cancer-related mortality worldwide. With increasing life expectancy and improved screening techniques, its incidence continues to rise. While conventional treatments—hormone therapy, chemotherapy, and radiotherapy—can control the disease in its early stages, their effectiveness significantly declines as the cancer progresses into more aggressive forms.
Metastatic castration-resistant prostate cancer (mCRPC) exemplifies this challenge. This advanced stage of the disease is characterized by loss of sensitivity to hormonal treatments, leading to uncontrolled tumor progression, often accompanied by bone and visceral metastases. This resistance is driven by complex mechanisms, such as alterations in androgen signaling pathways or tumor mutations that promote therapeutic escape. The available treatments for mCRPC patients are therefore limited and show reduced long-term efficacy. It is crucial to develop innovative and targeted approaches to improve patient management.
In this context, prostate-specific membrane antigen (PSMA) has emerged as a key target in the fight against prostate cancer. Highly overexpressed in tumor cells, PSMA has transformed diagnostic and therapeutic approaches, enabling precise detection and effective targeting of cancer cells. Among the major advancements, radioligand therapy (RLT) using lutetium-177 ([177Lu]Lu-PSMA-617) has demonstrated promising results, particularly in the treatment of mCRPC.
Read next: A new avenue in the fight against prostate cancer?
PSMA, a promising therapeutic target?
This study focused on analyzing PSMA-targeted therapies in advanced and metastatic forms of prostate cancer. Several therapeutic approaches have been investigated: radiolabeled ligands targeting PSMA, anti-PSMA monoclonal antibodies, and antibody-drug conjugates (ADC). The trials evaluated antitumor efficacy, PSMA receptor binding rates, tumor marker (PSA) reduction, and metastatic progression.The safety and efficacy of treatments were also assessed, with particular attention to side effects (renal and hematological toxicities). The trials included mCRPC patients, meeting strict criteria (ECOG score ≤ 2 and confirmed PSMA overexpression by molecular imaging). The results were compared to conventional treatments to evaluate the specific benefits of PSMA-targeting approaches.
The study results demonstrate that PSMA-targeted therapies have led to a significant improvement in overall survival (OS) and radiographic progression-free survival (rPFS) in mCRPC patients. The VISION trial reported an increase in rPFS by 5.3 months and OS by 4 months compared to standard treatments. However, approximately 17% to 30% of patients exhibit primary resistance to this therapy, primarily due to tumor heterogeneity and immune escape mechanisms.
Read next: HER2, the key to revolutionizing cancer treatment
PSMA, a revolution in prostate cancer treatment
Prostate cancer is one of the most common cancers in men and a major cause of global mortality. Advanced forms (mCRPC) remain particularly difficult to treat, highlighting the limitations of traditional treatments, especially hormone therapy and chemotherapy. PSMA-targeted therapy has emerged as a major innovation, offering a significant improvement in survival and quality of life for mCRPC patients. The goal of this approach is to precisely target tumor cells that overexpress PSMA, while limiting damage to healthy tissues.The results show that this revolutionary therapy enhances survival prospects for patients with advanced cancers, but remains limited by significant challenges. Common toxicities, high costs, and the complex production of radiopharmaceuticals hinder its widespread adoption.
Despite these limitations, promising research is focusing on optimizing PSMA-targeted therapy. The combination with immune checkpoint inhibitors (PD-1/PD-L1) or DNA repair agents could enhance its efficacy and overcome resistance. Furthermore, the exploration of alternative isotopes opens new perspectives for increased efficacy and reduced side effects. With ongoing clinical trials and continuous advancements, PSMA-targeted therapy is well-positioned to transform the management of advanced or resistant prostate cancers.
Read next: Can Diet Be a Weapon Against Prostate Cancer?
Last press reviews
PSMA, a revolution against prostate cancer
#ProstateCancer #Cancer #Prostate #Therapy #Inno...
HER2, the key to revolutionizing cancer treatment
#Oncology #Cancer #HER2 #TargetedTherapy #Therap...
CD47: The Tumor Shield Finally Broken?
#cancer #immunotherapy #CD47 #innovation ...